DOWNSTREAM PROCESSING FEATURED ARTICLES
Millipore Unveils Mobius FlexReady Solutions At INTERPHEX 2009
-
Lpath Receives First U.S. Patent For Anti-LPA Antibody, Lpathomab
Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that it has been issued a key patent protecting Lpathomab™, a monoclonal antibody against lysophosphatidic acid (LPA).
-
Thallion And LFB Terminate Shigamabs Collaboration
Thallion Pharmaceuticals Inc. (TSX-V: TLN) ("Thallion") and LFB Biotechnologies ("LFB") today announced that they have reached an agreement on the termination of their Development and Licensing Agreement related to Thallion's Shigamabs® program.
-
Novavax Publishes Preclinical Efficacy Study Of Its RSV Protein Nanoparticle Vaccine Candidate
Novavax, Inc. (Nasdaq: NVAX) today announced that the journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0050852) published data from a preclinical study of its recombinant nanoparticle vaccine candidate against respiratory syncytial virus (RSV), demonstrating efficacy and safety in a well-established animal model.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
White Paper: Comparability Of The Cell-Freeze® (Charter Medical) Freezing Bag To The Cryocyte™ (Baxter) Bag For Cryogenic Storage Of Human Hematopoietic Progenitor Cells Successful cryopreservation of hematopoietic progenitor cells (HPC) is dependent upon a number of factors, including the biopreservation media, freezing rates, and storage using sterile, cryogenically durable storage bags. The Cell-Freeze® cryogenic storage containers are 510(k) cleared for storage, preservation and transfer of hematopoietic progenitor stem cells (HPC’s). By Charter Medical, Ltd.
-
Important Considerations For Implementing A Single-Use Biomanufacturing Strategy
Recent trends in biomanufacturing technology and the biopharmaceutical market are supporting the increased adoption of single-use (SU) manufacturing systems. On the demand-side, the biopharma industry is focusing on niche and rare diseases with smaller patient populations, resulting in the need for smaller, more agile biomanufacturing capacity. By Jodi M. Zobrist and Nicole W. O'Brien, Ph. D., Gallus Biopharmaceuticals, LLC
-
Micro-Volume Determination Of Labeling Efficiency In A Standard Microplate Reader
A variety of methods and reagents have been developed to efficiently label biomolecules. By Peter J. Brescia, Applications Scientist, BioTek Instruments, Inc.
-
Examining Column Reproducibility During Method Development In Clinical Labs
In this study demonstrates how the HSS T3 stationary phase is a reliable stationary phase, as three batches made over a five-year span provide comparable results.
-
Materials Of Construction For Biopharmaceutical Water Systems
Stainless steels are uniquely qualified for bioprocessing applications not only because of their long service life, availability, and fabricability, but also because they are non-corroding, non-contaminant, can be polished to very smooth finishes, are strong and rigid, can withstand heat and chemical sterilization treatments, and are easily welded. By Michelle M. Gonzalez
-
Managing Cell-Based Potency Assays: From Development To Lifecycle Maintenance
Characterization of a biological product — which includes the determination of physicochemical properties, biological activity, immunochemical properties, purity and impurities — is necessary to establish the safety and efficacy profile of a given product (ICH Q6B). By Dr. Weihong Wang, manager, Molecular and Cell Biology, Eurofins Lancaster Laboratories